Cancer Research Technology
Log in Register
Menu

pCMV-iNOS Vector

Invented by Dr Helen McCarthy at Queen's University Belfast

Info

Catalogue Number 153287
Bacterial Resistance Kanamycin
Vector Type pcDNA 3.1
Synonyms Nitric Oxide Synthase
Antigen/Gene or Protein Targets Inducible Nitric Oxide Synthase
Relevance pCMV-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a constitutively active CMV (cytomegalovirus) promoter. Originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies that address hormone refractory prostate cancer (HRPC). Studies in the literature have demonstrated that this plasmid is capable of delaying tumour growth (Adams et al., 2009). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation.
Research Area Cancer, Metabolism, Neurobiology
Notes Recommended for transpormation in DH5 alpha bacterial cells
iNOS gene is 4.4kb

References

There are 10 reference entries for this reagent.

View All References

References: 10 entries

Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.

Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.

Europe PMC ID: 19062185

Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

Europe PMC ID: 18256696

McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.

Europe PMC ID: 17471586

McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.

p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.

Europe PMC ID: 17006546

Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.

Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.

Europe PMC ID: 11896465


Add a reference

References: 10 entries

Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.

Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.

Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.

McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.

p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.

Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.

Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.


Add a reference